Vinorelbine, a second-generation Vinca alkaloid - its place in the treatment of advanced and metastatic breast cancer
2014
Abstract
Vinorelbine (originally in intravenous form) has shown efficacy both in combination therapy and as a single agent in patients with metastatic breast cancer. When used in first-line monotherapy of metastatic breast cancer it was associated with 40-60% overall response rate.
Further development of vinorelbine therapy followed the introduction of oral dosage form of the agent. Vinorelbine has demonstrated efficacy in combination with the mTOR inhibitor everolimus as well as in combination with lapatinib, while combinations with trastuzumab and pertuzumab are still undergoing testing.